Deleted Tweets From Scott Gottlieb, R-D.C.

Finally, regulatory science develops tools, standards and approaches to help facilitate product development. One tool is the Antimicrobial Resistance Isolate Bank with the @CDCgov https://t.co/SbqokgRrOZ. It provides curated microbe strains to researchers and product developers. https://t.co/rgBvgz72K1

Finally, regulatory science develops tools, standards and approaches to help facilitate product development. One tool is the Antimicrobial Resistance Isolate Bank with the @CDCgov https://t.co/SbqokgRrOZ. It provides curated microbe strains to researchers and product developers. https://t.co/cni2IsKPni

I’m confident these and future efforts will help us achieve our goal of facilitating antimicrobial stewardship and advancing innovation across human and animal health, within our borders and across them. https://t.co/oL4HCgjnyn

The commitment of @SecAzar to addressing kids use of nicotine products, including e-cigs, underscores the public health commitment of his department. Our data shows the rise in use of e-cigs among kids from 2017-18 is shocking. We'll end this epidemic. https://t.co/L2XEhs7CdT

RT @SGottliebFDA: Antimicrobial resistance (AMR) is a growing threat. In today’s #FDA #SUNDAYTWEETORIAL, I’m going to talk about this… https://t.co/ZXa99owk4T

RT @endpts: Antimicrobial resistance: FDA discusses reimbursement reforms by @ZacharyBrennan via @RAPSorg… https://t.co/S1SEF1adyO

Join us Oct. 24 and 25, for an Advisory Committee meeting to review what we've learned and consider how we should move forward with cardiovascular risk assessment for future glucose lowering therapies. https://t.co/DdSnIJtF5z

THREAD: Type 2 diabetes impacts millions of Americans each year and the #FDA is committed to the development of drugs to help manage of this disease.

This is why we released a guidance in 2008 to ensure that drugs developed for treatment of type 2 diabetes were not associated with an unacceptable increase of cardiovascular risk. Over the last 10yrs we've accrued a body of data about this topic.

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept. https://t.co/vKOhCgZjP5

Coming Soon: Generic drug manufacturers and related industry can submit their controlled correspondence via the CDER Direct NextGen Collaboration Portal: https://t.co/boT791JkwG.

Visit our webpage for more information: https://t.co/SrNRYZfntP

RT @CDCDirector: CDC is working to prevent injuries, detect and respond to the emergence of disease, and foster the physical and men… https://t.co/GQLegUbeTO

RT @SecAzar: Thanks to @POTUS and the National Biodefense Strategy, @HHSGov will coordinate efforts across the government to def… https://t.co/Ntpo1B77Oh

RT @FDATobacco: As part of FDA’s ongoing efforts to reduce the enormous public health burden of tobacco use, the agency is unveilin… https://t.co/yvNqGnIZ9k

RT @US_FDA: A4: FDA is working w/ @NIH on a public-private partnership to develop new alternative pain treatments, including sa… https://t.co/xIuQd7AAUu

RT @FDAMedia: FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of ne… https://t.co/GaJrj17qPx

RT @SGottliebFDA: THREAD: 1/5 Today, #FDA launched a new, comprehensive campaign to warn kids about the dangers of e-cigarette use as… https://t.co/M3GltMlIT0

We are delighted to welcome Stacy Amin as the #FDA’s new chief counsel. She brings a wide breadth of experience in healthcare, law and policy; an unflinching devotion to the public health; and a deep understanding of, and appreciation for, the special mission of our agency.

RT @theNCI: NCI and @US_FDA are sponsoring a challenge to spur the development of methods to detect and correct mislabeled tumo… https://t.co/GHW16LDYby

Finally, regulatory science develops tools, standards and approaches to help facilitate product development. One tool is the Antimicrobial Resistance Isolate Bank with the @CDCgov https://t.co/SbqokgRrOZ. It provides curated microbe strains to researchers and product developers. https://t.co/rgBvgz72K1

Finally, regulatory science develops tools, standards and approaches to help facilitate product development. One tool is the Antimicrobial Resistance Isolate Bank with the @CDCgov https://t.co/SbqokgRrOZ. It provides curated microbe strains to researchers and product developers. https://t.co/cni2IsKPni

I’m confident these and future efforts will help us achieve our goal of facilitating antimicrobial stewardship and advancing innovation across human and animal health, within our borders and across them. https://t.co/oL4HCgjnyn

The commitment of @SecAzar to addressing kids use of nicotine products, including e-cigs, underscores the public health commitment of his department. Our data shows the rise in use of e-cigs among kids from 2017-18 is shocking. We'll end this epidemic. https://t.co/L2XEhs7CdT

RT @SGottliebFDA: Antimicrobial resistance (AMR) is a growing threat. In today’s #FDA #SUNDAYTWEETORIAL, I’m going to talk about this… https://t.co/ZXa99owk4T

RT @endpts: Antimicrobial resistance: FDA discusses reimbursement reforms by @ZacharyBrennan via @RAPSorg… https://t.co/S1SEF1adyO

Join us Oct. 24 and 25, for an Advisory Committee meeting to review what we've learned and consider how we should move forward with cardiovascular risk assessment for future glucose lowering therapies. https://t.co/DdSnIJtF5z

THREAD: Type 2 diabetes impacts millions of Americans each year and the #FDA is committed to the development of drugs to help manage of this disease.

This is why we released a guidance in 2008 to ensure that drugs developed for treatment of type 2 diabetes were not associated with an unacceptable increase of cardiovascular risk. Over the last 10yrs we've accrued a body of data about this topic.

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept. https://t.co/vKOhCgZjP5

Coming Soon: Generic drug manufacturers and related industry can submit their controlled correspondence via the CDER Direct NextGen Collaboration Portal: https://t.co/boT791JkwG.

Visit our webpage for more information: https://t.co/SrNRYZfntP

RT @CDCDirector: CDC is working to prevent injuries, detect and respond to the emergence of disease, and foster the physical and men… https://t.co/GQLegUbeTO

RT @SecAzar: Thanks to @POTUS and the National Biodefense Strategy, @HHSGov will coordinate efforts across the government to def… https://t.co/Ntpo1B77Oh

RT @FDATobacco: As part of FDA’s ongoing efforts to reduce the enormous public health burden of tobacco use, the agency is unveilin… https://t.co/yvNqGnIZ9k

RT @US_FDA: A4: FDA is working w/ @NIH on a public-private partnership to develop new alternative pain treatments, including sa… https://t.co/xIuQd7AAUu

RT @FDAMedia: FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of ne… https://t.co/GaJrj17qPx

RT @SGottliebFDA: THREAD: 1/5 Today, #FDA launched a new, comprehensive campaign to warn kids about the dangers of e-cigarette use as… https://t.co/M3GltMlIT0

We are delighted to welcome Stacy Amin as the #FDA’s new chief counsel. She brings a wide breadth of experience in healthcare, law and policy; an unflinching devotion to the public health; and a deep understanding of, and appreciation for, the special mission of our agency.

RT @theNCI: NCI and @US_FDA are sponsoring a challenge to spur the development of methods to detect and correct mislabeled tumo… https://t.co/GHW16LDYby